Has Amber Whitton-Smith, NP received payments from drug or device companies?

Yes. Drug and device makers reported $7,131 in general payments to Amber Whitton-Smith, NP across 289 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amber Whitton-Smith, NP did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amber Whitton-Smith, NP come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amber Whitton-Smith, NP

Nurse Practitioner · Denver, CONPI 1689823593

Payments from drug & device makers

$7,131in general payments, 2019–2025

Across 289 payments — averaging $24.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$813
Novartis$395
AstraZeneca$373
Pfizer$319
Seagen Inc.$294
Gilead$288
plus $5K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(2 entities)	26	$813
Novartis	19	$395
AstraZeneca(2 entities)	18	$373
Pfizer	17	$319
Seagen Inc.	7	$294
Gilead	12	$288
E.r. Squibb & Sons, L.L.C.	12	$275
Lilly USA, LLC	8	$258
Pharmacyclics LLC, An Abbvie Company	6	$235
Daiichi Sankyo Inc.	11	$229
GSK	9	$226
AVEO Pharmaceuticals, Inc.	6	$220
Sanofi	8	$212
Sobi, Inc	7	$212
Merck	10	$204
Bristol Myers Squibb	9	$196
Exelixis Inc.	4	$176
Genentech USA, Inc.	8	$165
Karyopharm Therapeutics Inc.	6	$153
Rigel Pharmaceuticals, Inc.	6	$124
Genmab U.S., Inc.	4	$112
Astellas Pharma US Inc	4	$104
Eisai Inc.	5	$101
Amgen	5	$100
Tersera Therapeutics LLC	5	$99
Sanofi-aventis U.S. LLC	1	$87
Regeneron Healthcare Solutions, Inc.	3	$69
Beigene USA, Inc.	3	$68
Pharmaessentia USA Corporation	3	$63
Ipsen Biopharmaceuticals, Inc	3	$57
Alnylam Pharmaceuticals Inc.	3	$57
ADC Therapeutics America, Inc.	3	$56
CTI Biopharma Corp.	2	$53
Takeda Pharmaceuticals U.S.A., Inc.	2	$52
Recordati_rare_diseases_inc.	2	$47
Incyte Corporation	2	$40
Immunocore Limited	2	$39
Beone Medicines USA, Inc.	2	$37
AbbVie	1	$33
Monteris Medical Corporation	1	$31
Myriad Genetic Laboratories, Inc.	1	$31
Taiho Oncology, Inc.	2	$30
Sumitomo Pharma America, Inc.	1	$25
Springworks Therapeutics, Inc.	1	$25
EUSA Pharma (US) LLC	1	$24
Mirati Therapeutics, Inc.	1	$23
Dendreon Pharmaceuticals LLC	1	$23
Blueprint Medicines Corporation	1	$22
Stemline Therapeutics Inc.	1	$22
Sun Pharmaceutical Industries Inc.	1	$20
EMD Serono, Inc.	1	$20
Servier Pharmaceuticals LLC	1	$18
Tempus AI, Inc	1	$18
Foundation Medicine, Inc.	1	$18
Dova Pharmaceuticals	1	$18
Pharmacosmos Therapeutics Inc.	1	$17
TG Therapeutics, Inc.	1	$17
Organon	1	$17
Morphosys, US Inc.	1	$17
Boehringer Ingelheim	1	$15

How this compares

$7,131 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

See all nurse practitioner providers in Colorado →

Medicare billing

Part B allowed, 2024

$14,326

Medicare patients

136

Services billed

219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Denver

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →